Stock Analysis · August 14, 2026
Johnson & Johnson: Quality, But Less Margin for Error
JNJ combines durable healthcare franchises and strong cash conversion with a valuation that now requires continued pipeline execution and a clean resolution of legacy liabilities.
Executive Summary
Johnson & Johnson remains a high-quality defensive healthcare franchise, but it is no longer valued like a conventional recession shelter. The stock has gained 49.3% over 52 weeks and closed at $260.35 on August 14, leaving the consensus $272.50 target only 4.7% away. That is a sound setup for owners who value dependable cash generation and pipeline optionality, not an invitation to ignore execution risk.
The investment case rests on two scaled engines—Innovative Medicine and MedTech—plus $22.24 billion of trailing free cash flow. The nearer-term tension is visible: management maintained 2026 revenue guidance of $100.8 billion to $101.4 billion, while the Firefly Bio acquisition and Sail Biomedicines collaboration reduced its 2026 adjusted EPS outlook to $10.86–$11.01. A Hold / accumulate-on-weakness stance best matches a premium franchise whose upside depends more on delivery than on multiple expansion.
90-Day Price and Trend
Closing-price checkpoints through August 14, 2026. The 50-day simple moving average is shown as a trend reference; moving averages are descriptive, not forecasts.
Company Overview
Johnson & Johnson operates through Innovative Medicine and MedTech. The pharmaceutical business spans oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. MedTech adds surgical, orthopaedic, cardiovascular and vision platforms, giving the group a second source of growth that is less exposed to any one drug cycle.
That breadth is the central defensive attribute. Healthcare utilization and procedure volumes can fluctuate, but the company is not a single-product story. Its 138,200 employees, global distribution, and relationships with providers and payers give it a scale advantage; the trade-off is that meaningful growth requires disciplined portfolio choices, regulatory success and sustained innovation across multiple therapeutic areas.
- Sector
- Healthcare
- Market cap
- $627.4B
- Enterprise value
- $655.7B
- TTM EBITDA
- $34.9B
- TTM FCF/share
- $9.23
- Next ex-dividend
- Aug. 25
Industry and Market Analysis
Healthcare can provide earnings durability in a slowing economy because patient need is less discretionary than many consumer or industrial categories. That does not make the sector frictionless: drug-pricing policy, patent cycles, reimbursement, hospital budgets and trial outcomes all matter. JNJ's mix of Innovative Medicine and procedure-linked MedTech makes diversification a real operating advantage, while exposing the company to two distinct execution calendars.
| Street snapshot | Reading | Interpretation |
|---|---|---|
| Consensus rating | Buy | Sixteen of 23 tracked analysts are Buy or Strong Buy; six are Hold and one is Strong Sell. |
| Average 12-month target | $272.50 | Only 4.7% above the August 14 close, which limits room for valuation-led upside. |
| Forward P/E | 23.2× | Investors are paying for continued earnings delivery and pipeline confidence. |
| Beta | 0.23 | Low historical price sensitivity supports a defensive role, but does not eliminate company-specific risk. |
Technical Analysis
Trend
The $260.35 close stood above the 50-day average of $251.31 and the 200-day average of $229.78. The trend is positive, but the share price is also just 5.3% below its $274.90 52-week high.
Momentum
A 14-day RSI of 55.2 is constructive rather than stretched. The technical picture supports ownership, but does not independently establish a wide margin of safety.
Risk reference
The 50-day average near $251 is the first trend reference. A sustained loss of that level would shift attention toward the 200-day average and the durability of the fundamental rerating.
Fundamental Analysis
Trailing revenue is $97.93 billion, up 8.1%, while operating income is $27.12 billion and free cash flow is $22.24 billion. A 27.7% operating margin and 22.7% free-cash-flow margin show why JNJ is valued as a quality compounder. The annual dividend of $5.36 has increased for 64 consecutive years, with a 62.1% payout ratio that leaves some capacity for reinvestment.
Balance-sheet leverage is manageable rather than trivial: $49.04 billion of debt is offset by $20.76 billion of cash, and debt-to-EBITDA is 1.4×. The key valuation issue is not financial survival; it is whether cash-flow growth can justify 28.2× trailing free cash flow after a powerful share-price run.
What to watch next
- 2026 revenue delivery within the $100.8B–$101.4B guide
- Margin and EPS effects from Firefly Bio and Sail Biomedicines
- MedTech procedure growth and OTTAVA commercialization milestones
- Oncology and immunology pipeline readouts and regulatory decisions
- Cash deployment, dividend coverage and net-debt discipline
Risk Analysis
| Risk | Why it matters | Investor signpost |
|---|---|---|
| Litigation | The proposed $5.5 billion talc settlement could reduce a long-running overhang, but final resolution and residual exposure remain material. | Settlement progress, cash uses and disclosures. |
| Acquisition integration | Firefly Bio and the Sail collaboration broaden the pipeline but are expected to dilute 2027 adjusted EPS. | Milestones, integration costs and revised return expectations. |
| Pipeline and competition | Premium valuation assumes innovative-medicine franchises and new launches can offset competition and lifecycle pressure. | Trial data, approvals and prescription trends. |
| Policy and pricing | Drug pricing, reimbursement and provider budgets can pressure realized economics. | Policy changes and net-price trends. |
| Valuation | With modest consensus-target upside, multiple compression can outweigh otherwise solid operating execution. | Forward earnings revisions and cash-flow growth. |
Bottom Line
JNJ is a defensible core healthcare holding, supported by diversified franchises, sizable free cash flow and a long dividend record. The appropriate discipline is price-aware ownership: the business quality is evident, while the current quotation leaves less room for disappointment. Investors should look for revenue delivery, evidence that new pipeline investments earn their cost of capital, and continued progress toward resolving the talc overhang before treating the stock as a broad-based bargain.